Burning Rock Biotech (NASDAQ:BNR) Trading 2.8% Higher - Time to Buy?

Key Points

• Burning Rock Biotech's stock traded up 2.8% to $8.59, despite a significant decline in trading volume, which was down 41% from the average session.
• Weiss Ratings reiterated a "sell (d-)" rating on the stock, contributing to an overall average rating of "Sell" from analysts.
• In its latest quarterly earnings, Burning Rock Biotech reported a loss of ($0.15) earnings per share and a revenue of $20.74 million, with negative returns on equity and net margin.

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Get Free Report) traded up 2.8% during trading on Monday . The stock traded as high as $8.59 and last traded at $8.59. 13,289 shares changed hands during trading, a decline of 41% from the average session volume of 22,362 shares. The stock had previously closed at $8.36.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Burning Rock Biotech in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Burning Rock Biotech presently has an average rating of "Sell".

Burning Rock Biotech Stock Up 2.8%

The company's 50-day moving average is $8.48 and its two-hundred day moving average is $5.35. The company has a market capitalization of $92.43 million, a P/E ratio of -4.52 and a beta of 0.98.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last posted its quarterly earnings data on Monday, September 8th. The company reported ($0.15) earnings per share for the quarter. The company had revenue of $20.74 million during the quarter. Burning Rock Biotech had a negative return on equity of 23.61% and a negative net margin of 26.04%.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.